Neurodegenerative diseases are in fact a collection of dozens of complex diseases that are growing in prevalence and are becoming one of the world’s most formidable public health challenges. Over the next two decades, a number of disease types, including Alzheimer’s and MS are expected to soar with increases predicted to be in the range of 50%. There are no cures for these diseases through drug therapies and the new generation of drugs that target these diseases still only treat symptoms.
Over 16 million people in the US alone are currently living with a chronic brain disease or disorder that requires either long-term care and/or support from family caregivers. More than one million adults in the U.S. are diagnosed annually with a chronic brain disease or disorder. Many of these conditions, for example, MS, ALS, Alzheimer’s, and Parkinson’s, are associated with increasing age. Given the aging US population, figures will increase proportionately in the coming decades. Significantly, each disorder is also increasing in prevalence in all age categories including multiple sclerosis (MS) which is approximately 50% higher than it was 25 years ago. The current statistical research was published in a comprehensive review conducted by the National Institutes of Neurological Disorders and Stroke updating US prevalence and incidence data of 12 neurological conditions commonly seen by neurologists.
Cell replacement therapies for diseased and injured brain tissue have provided the basis for the development of powerful new therapeutic strategies for a broad spectrum of these neurological diseases. Efforts to develop suitable cell types for cell replacement therapies in patients suffering from these diseases has until recently, held back the development of this promising therapeutic approach. Recent clinical trials have identified the cell types required to allow every type of tissue regeneration required for successful therapeutic outcomes. Third-party suppliers of cellular material and growth factors for in vitro proliferation have now successfully engineered both products and techniques that allow rapid growth of stem cells. Regenetek Research has merged these new findings into a therapeutic approach that has overcome these barriers to provide safe and effective therapies for potentially millions of people. Recent patient outcomes have provided further evidence that the approach will continue to be effective.